Trial of Tolcapone With Oxaliplatin for Neuroblastoma



Status:Recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 21
Updated:4/21/2018
Start Date:December 2015
End Date:December 2020
Contact:Genevieve Bergendahl, MSN
Email:genevieve.bergendahl@helendevoschildrens.org
Phone:6162670335

Use our guide to learn which trials are right for you!

A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma

The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone
and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is
approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational
drug in this study because it has not been approved in pediatrics for this indication.
Oxaliplatin, although a drug approved by the FDA for other cancers, is investigational for
treatment of neuroblastoma in this study. This study will look at the safety and tolerability
of tolcapone in combination with oxaliplatin as well as the tumors response to this study
drug.


Inclusion Criteria:

1. Age: ≤ 21 years at the time of study entry.

2. Diagnosis: Histologic verification at either the time of original diagnosis or relapse
of neuroblastoma.

3. Disease Status: Patients must have ONE of the following:

- Any episode of recurrent disease following completion of aggressive multi-drug
frontline therapy.

- Any episode of progressive disease during aggressive multi-drug frontline
therapy.

- Primary resistant/refractory disease detected at the conclusion of at least 4
cycles of aggressive multidrug induction chemotherapy on or according to a
high-risk neuroblastoma protocols.

4. Measurable or evaluable disease, including at least one of the following: measureable
tumor by CT or MRI; a positive MIBG, or PET scan; positive bone marrow
biopsy/aspirate.

5. Current disease state must be one for which there is currently no known curative
therapy

6. A negative urine or serum pregnancy test is required for female subjects of child
bearing potential (onset of menses or ≥13 years of age).

7. Organ Function Requirements:

- Subjects must have adequate liver function as defined by:

- AST and ALT ≤ upper limit of normal

- Serum bilirubin must be ≤ 2.0 mg/dl

- Subjects must have adequate Bone Marrow function defined as:

For patients without bone marrow involvement:

• Peripheral absolute neutrophil count (ANC) >750/uL

- Subjects must have adequate renal function

- Both male and female post-pubertal study subjects need to agree to use one of the more
effective birth control methods during treatment and for 90 days after treatment is
stopped. These methods include total abstinence (no sex), oral contraceptives ("the
pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or
medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be
used, contraceptive foam with a condom is recommended.

- Informed Consent: All subjects and/or legal guardians must sign informed written
consent. Assent, when appropriate, will be obtained according to institutional
guidelines.

Exclusion Criteria:

- Lansky score <50%

- BSA (m2) of <0.5

- Prior Therapy- Patients must have fully recovered from the acute toxic effects of all
prior anti- cancer chemotherapy and be within the following timelines:

- Myelosuppressive chemotherapy: Must not have received within 2 weeks of
enrollment onto this study (6 weeks if prior nitrosourea).

- Hematopoietic growth factors: At least 5 days since the completion of therapy
with a growth factor.

- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
with a biologic agent. For agents that have known adverse events occurring beyond
7 days after administration, this period must be extended beyond the time during
which adverse events are known to occur. The duration of this interval must be
discussed with the Study Chair.

- Immunotherapy: At least 6 weeks since the completion of any type of
immunotherapy, e.g. tumor vaccines.

- Monoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must
have elapsed since prior treatment with a monoclonal antibody.

- XRT: At least 14 days since the last treatment except for radiation delivered
with palliative intent to a non-target site.

- Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and
≥ 2 months must have elapsed since transplant.

- Investigational Drugs: Subjects who have received another investigational drug within
the last 14 days are excluded from participation.

- Subjects with CNS lesions are excluded

- Subjects with a history of depression, anxiety, or psychotic disorders (due to
tolcapone adverse event profile).

- Subjects that are pregnant or breastfeeding an infant.

- Subjects that cannot swallow tablets.

- Infection: Subjects who have an uncontrolled infection are not eligible until the
infection is judged to be well controlled in the opinion of the investigator.

- Subjects who, in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study, or in whom compliance is likely to be
suboptimal, should be excluded.
We found this trial at
9
sites
San Diego, California 92123
Principal Investigator: William Roberts, MD
Phone: 858-966-8155
?
mi
from
San Diego, CA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Jaqueline Kraveka, MD
Phone: 843-792-2957
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Javier Oesterheld, MD
Phone: 980-442-2355
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Deanna Mitchell, MD
Phone: 616-267-1162
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Hartford, Connecticut 06106
Principal Investigator: Michael Isakoff, MD
Phone: 860-545-9337
?
mi
from
Hartford, CT
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Valerie Brown, MD
?
mi
from
Hershey, PA
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
(808) 983-6000
Principal Investigator: Randal Wada, MD
Phone: 808-535-7169
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Kathleen Neville, MD
Phone: 501-364-2760
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Saint Louis, Missouri 63104
Principal Investigator: William Ferguson, MD
Phone: 314-268-4000
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials